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Abstract: The aim of this study was to analyze the antibacterial activity of four essential oils
(EOs), Melaleuca alternifolia, Eucalyptus globulus, Mentha piperita, and Thymus vulgaris, in preventing
the development and spread of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli
and Klebsiella pneumoniae, metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa and
carbapenemase (KPC)-producing Klebsiella pneumoniae. A total of 60 strains were obtained from the
stock collection from the Microbiology Laboratory of Hesperia Hospital, Modena, Italy. Twenty ESBL-
producing E. coli, 5 K. pneumoniae, 13 KPC-producing K. pneumoniae, and 20 MBL-producing
P. aeruginosa were cultured and reconfirmed as ESBL and carbapenamase producers. Polymerase chain
reaction was used for the detection of genes responsible for antibiotic resistance (ESBL and KPC/MBL).
Antibacterial activity of the EOs was determined using the agar disk diffusion assay, and minimal
inhibitory concentrations (MICs) were also evaluated. Lastly, adhesion capability and biofilm
formation on polystyrene and glass surfaces were studied in 24 randomly selected strains. M. alternifolia
and T. vulgaris EOs showed the best antibacterial activity against all tested strains and, as revealed by
agar disk diffusion assay, M. alternifolia was the most effective, even at low concentrations. This effect
was also confirmed by MICs, with values ranging from 0.5 to 16 µg/mL and from 1 to 16 µg/mL,
for M. alternifolia and T. vulgaris EOs, respectively. The EOs’ antibacterial activity compared to
antibiotics confirmed M. alternifolia EO as the best antibacterial agent. T. vulgaris EO also showed
a good antibacterial activity with MICs lower than both reference antibiotics. Lastly, a significant
anti-biofilm activity was observed for the two EOs (*P < 0.05 and **P < 0.01 for M. alternifolia and
T. vulgaris EOs, respectively). A good antibacterial and anti-biofilm activity of M. alternifolia and T.
vulgaris EOs against all selected strains was observed, thus demonstrating a future possible use of
these EOs to treat infections caused by ESBL/carbapenemase-producing strains, even in association
with antibiotics.
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1. Introduction
The improper and uncontrolled use of antibiotics in human and veterinary medicine resulted
in the occurrence of multi drug resistant (MDR) strains, which have become a major health concern
worldwide [1–4]. MDR microorganisms, both Gram-positive and Gram-negative bacteria, are those
bacteria that acquired a non-susceptibility to one or more classes of antimicrobials as per in vitro tests [5,6].
The production of enzymes by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing
Gram-negative bacteria is a problem in most of hospital facilities worldwide. The widespread use of
antimicrobials, primarily antibiotics, and the transmissibility of resistance determinants mediated by
plasmids, transposons, and gene cassettes in integrons contributed to the spread of resistance [7].
This problem of increasing resistance imposed the search for safe and effective factors that might
be used to treat persistent bacterial infections. The severity and extent of diseases caused by these
pathogens are also amplified when the pathogens are organized in biofilms, the most relevant structures
responsible for persistent infections, that constitute a major challenge for microbiologists and clinicians.
A biofilm is a microorganisms’ community that produces an extracellular matrix to attach itself to
biotic or abiotic surfaces, embedded in an aqueous matrix of extracellular polymeric substances
(EPS) [8]. Bacteria growing in biofilms are commonly even more resistant to antimicrobial agents and
are protected from the host immune response, thus increasing chronic infections that are particularly
difficult to nurse [9,10]. One mechanism of biofilm resistance to antimicrobial agents is the failure of an
agent to penetrate the full depth of the biofilm. Biofilm resistance is supposed to be mediated by the
ability of some of the biofilm cells that, undergoing nutrient restriction, can persist in a slow-growing
or starved state. However, a recent theory proposed that at least some of the cells in a biofilm can
adopt a distinct and protecting biofilm phenotype [11].
Experimental studies have already confirmed different pharmaceutical activities not only of
chemical compounds, but also of many plant metabolites, such as polysaccharides, flavonoids,
coumarins, glycosides, phenolic acids, saponins, and essential oils (EOs). Plant metabolites are a very
interesting alternative for synthetic preparations, many of which are endowed with strong antimicrobial
activity [12,13]. Antibacterial effects of EOs and their compounds (s-(+)-linalool, terpinen-4-ol carvacrol,
eugenol) have been recently tested in many investigations against bacteria, both in planktonic and
sessile forms [14–16].
EOs are mixtures of compounds obtained from spices, aromatic herbs, fruits, and flowers, and their
antimicrobial properties against bacteria and fungi have long been known. Considering the increasing
resistance phenomenon in pathogens, both in hospital and community settings, investigations on the
antimicrobial activities, mode of action, and potential uses of EOs and their components have gained a new
popularity for study [17]. EOs have already demonstrated antimicrobial activity [18–21], with additive
and synergistic effects with antibiotics used against antibiotic resistant bacteria. Recent studies highlighted
the synergistic role of EOs with other antimicrobials and how these associations could be used to improve
the activity of some antibiotics, with consequent reduction of therapeutic doses [22–24].
The objective of the preliminary investigation was to firstly assess the antimicrobial activity of
some EOs obtained/extracted from four different spices, Melaleuca alternifolia and Eucalyptus globulus
(Myrtaceae Family) and Mentha piperita and Thymus vulgaris (Labiatae Family), against planktonic
and biofilm cells of MDR Gram-negative bacteria such as Escherichia coli (E. coli), Klebsiella pneumoniae
(K. pneumoniae), and Pseudomonas aeruginosa (P. aeruginosa), ESBL/carbapenemase-producing strains
involved in human nosocomial infections and susceptible only to colistin, imipenem, meropenem,
or ertapenem, depending on the bacterial strains.
2. Results
2.1. Phenotypic Identification of ESBLs and Carbapenamase
Gram-negative isolates were identified as E. coli, K. pneumoniae, and P. aeruginosa strains using
Vitek-2 (bioMérieux, Florence, Italy). Out of the 60 strains analyzed, 27 (45%) strains showed an
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increase (5 mm) in the inhibition zone diameter for cefotaxime and ceftazidime in the presence of
amoxicillin/clavulanic acid (AMC) compared to when these antibiotics were tested alone: These isolates
were classified as ESBL producers. Moreover, thirty-three (55.6%) out of 60 strains tested for the
NG-Test CARBA were positive, among these, thirteen (39.4%) were carbapenemase (KPC) and twenty
(60.6%) metallo-beta-lactamase (MBL).
2.2. Polymerase Chain Reaction and Sequencing of ESBL and Carbapenemase Genes
All the ESBL/carbapenamase-producing strains were directly sequenced by PCR and analyzed.
In the ESBL isolates the following genes were found (species/number of isolates): blaCTX-M-15
(E. coli/15), blaTEM-52 (E. coli/ 5; K. pneumoniae/2), and blaCTX-M-1(K. pneumoniae/5), whereas in the
carbapemase-producing strains, blaKPC-2 (K. pneumoniae/13), blaVIM-1 (P. aeruginosa/15), and blaVIM-2
(P. aeruginosa/5) genes were recovered.
2.3. Antibacterial Activity Evaluation of the Essential Oils
2.3.1. Agar Disk Diffusion Assay
The agar disk diffusion assay was employed as a screening test for the determination of
antimicrobial activities of the EOs, by measuring the zone of inhibition of the bacteria growth (mm).
The American Type Culture Collection (ATCC) strains were used as a positive control. The results
revealed that M. alternifolia EO had a wide antibacterial spectrum and inhibited the growth of almost
all tested strains (Figure 1).
In particular, the inhibition zone ranged from 21 to 30 mm for E. coli (8 strains, 40%), K. pneumoniae
(9 strains, 45.5%), and P. aeruginosa (8 strains, 40%) and from 31 to 40 mm for the remaining susceptible
E. coli (5 strains, 25%), K. pneumoniae (4 strains, 20%), and P. aeruginosa (3 strains, 15%). A good
antibacterial activity was also shown by T. vulgaris EO, with a range of inhibition zone from 21 to 30 mm
for E. coli (9 strains, 45%), K. pneumoniae (4 strains, 20%) and P. aeruginosa (2 strains, 10%), whereas the
remaining susceptible E. coli and K. pneumoniae showed a zone of inhibition ranging from 31 to 40 mm
for 1 strain (5%) and 6 strains (30%), respectively. M. piperita EO exhibited an antibacterial activity
similar to T. vulgaris EO, with an inhibition zone ranging from 6 to 20 mm. E. globous EO showed a very
low activity against all bacterial strains, with inhibition zone values from 0 to 10 mm. The inhibition
zone of the two antibiotics cefotaxime and meropenem against all clinical isolated strains confirmed
their antibiotic-resistance. The American Type Culture Collection (ATCC) strains (E. coli ATCC 25922,
K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853) were sensitive to EOs such as the clinically
isolated strains. No activity was detected for the negative control in any of the performed tests.
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Figure 1. Antibacterial activity of essential oils (EOs) meropenem and cefotaxime by agar disc assay. 
Ranges of inhibitory zone diameter for E. coli ESBL (A), E. coli ATCC 25922 (B), K. pneumoniae 
ESBL/KPC (C), K. pneumoniae ATCC 700603 (D), P. aeruginosa MBL (E), and P. aeruginosa ATCC 27853 
(F). ESBL: extended-spectrum β-lactamase; ATCC: American Type Culture Collection; KPC: 
carbapenemase; MBL: metallo-beta-lactamase. 
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2.3.2. Minimal Inhibitory Concentration (MIC)
Figure 2 shows the minimal inhibitory concentration (MIC) values for EOs and for the two
antibiotics (cefotaxime and meropenem) used.
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Figure 2. Minimal inhibitory concentration (MIC) for (A) M. alternifolia, (B) M. piperita, (C) T. vulgaris,
(D) E. globulus, (E) cefotaxime, and (F) meropenem against E. coli ESBL, E. coli ATCC 25922, K. pneumoniae
ESBL/KPC, K. pneumoniae ATCC 700603, P. aeruginosa MBL, and P. aeruginosa ATCC 27853. All values
were reported to a 100% total.
Before describing MIC values for each essential oil on each strain, the values were reported
to a 100% total. A good antibacterial activity was observed for M. alternifolia and T. vulgaris EOs,
as already observed with the agar disk diffusion assay. MIC values of M. alternifolia EO ranged from
0.5 to 16 µg/mL; in particular, a percentage of 55% of K. pneumoniae, 45% of P. aeruginosa, and 95% of
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E. coli presented MICs between 0.5 and 4 µg/mL. MIC values ranging from 1 to 16 µg/mL emerged
for T. vulgaris EO, in a percentage of 90% for K. pneumoniae and P. aeruginosa and 85% for E. coli.
Regarding M. piperita and E. globulus, the MIC ranges were from 8 to 128 µg/mL and from 32 to 64
µg/mL, respectively, with a percentage of 90% for K. pneumoniae, 80% of P. aeruginosa, and 95% of E. coli.
Cefotaxime and meropenem MICs of all clinical isolates confirmed the antibiotic resistance patterns.
Lastly, the EOs’ antibacterial activity compared to antibiotics confirmed that M. alternifolia EO was
the most active against all clinical strains even at low concentrations; T. vulgaris EO also showed a good
activity with MICs lower than those of the two antibiotics used. Based on these results M. alternifolia
and T. vulgaris EOs were selected for the antibiofilm study.
2.4. Biofilm Assay
Antibiofilm activities of M. alternifolia and T. vulgaris EOs against the 24 randomly selected strains
are shown in Tables 1–3.
Table 1. E. coli biofilm values expressed as optical density with mean ± standard deviation (* P < 0.05).
Strain Positive M. alternifolia T. vulgaris Meropenem Cefotaxime
E. coli 5A 2.19 ± 0.07 0.61 ± 0.11 0.56 ± 0.03 * 0.87 ± 0.03 1.92 ± 0.06
E. coli 5M 2.17 ± 0.01 0.76 ± 0.05 0.64 ± 0.08 * 0.93 ± 0.03 1.88 ± 0.07
E. coli 5Z 2.04 ± 0.03 0.43 ± 0.10 0.43 ± 0.10 0.83 ± 0.05 1.88 ± 0.04
E. coli 6I 1.89 ± 0.09 0.68 ± 0.01 0.44 ± 0.09 * 0.87 ± 0.07 1.86 ± 0.07
E. coli 7B 1.91 ± 0.06 0.25 ± 0.06 * 0.47 ± 0.11 0.85 ± 0.08 1.84 ± 0.08
E. coli 7C 1.92 ± 0.04 0.34 ± 0.06 * 0.45 ± 0.12 0.84 ± 0.08 1.83 ± 0.11
E. coli 7D 1.95 ± 0.06 0.45 ± 0.07 0.23 ± 0.09 * 0.92 ± 0.08 1.89 ± 0.11
E. coli 7E 1.95 ± 0.06 0.45 ± 0.07 0.23 ± 0.09 * 0.92 ± 0.08 1.89 ± 0.11
E. coli ATCC 25922 2.11 ± 0.09 0.58 ± 0.08 * 0.33 ± 0.08 0.55 ± 0.13 0.39 ± 0.12
Table 2. K. pneumoniae biofilm values expressed as optical density with mean ± standard deviation
(* P < 0.05, ** P < 0.01).
Strain Positive M. alternifolia T. vulgaris Meropenem Cefotaxime
K. pneumoniae 1B 1.91 ± 0,06 0.71 ± 0.05 0.27 ± 0.03 1.42 ± 0.04 1.49 ± 0.05
K. pneumoniae 1C 1.88 ± 0.10 0.61 ± 0.04 * 0.86 ± 0.04 1.45 ± 0.05 1.39 ± 0.02
K. pneumoniae 1D 1.95 ± 0.15 0.35 ± 0.11 * 0.31 ± 0.17 * 1.16 ± 0.21 0.92 ± 0.05
K. pneumoniae 1E 1.99 ± 0.10 0.22 ± 0.09 * 0.44 ± 0.08 0.95 ± 0.13 1.00 ± 0.14
K. pneumoniae 1F 2.01 ± 0.10 0.37 ± 0.08 * 0.54 ± 0.08 0.96 ± 0.14 0.86 ± 0.10
K. pneumoniae 1G 2.01 ± 0.11 0.55 ± 0.13 * 0.78 ± 0.03 1.79 ± 0.10 1.78 ± 0.05
K. pneumoniae 1H 2.05 ± 0.10 0.43 ± 0.07 0.21 ± 0.04 * 1.80 ± 0.07 1.68 ± 0.04
K-pneumoniae 1V 2.91 ± 0.02 0.73 ± 0.09 0.45 ± 0.06 ** 0.90 ± 0.08 1.04 ± 0.11
K. pneumoniae ATCC 700603 2.04 ± 0.07 0.19 ± 0.01 0.12 ± 0.003 * 0.17 ± 0.06 0.34 ± 0.12
Table 3. P. aeruginosa biofilm values expressed as optical density with mean ± standard deviation
(* P < 0.05).
Strain Positive M. alternifolia T. vulgaris Meropenem Cefotaxime
P. aeruginosa 3A 1.85 ± 0.46 0.24 ± 0.12 0.35 ± 0.08 1.84 ± 0.07 1.75 ± 0.09
P. aeruginosa 3B 2.03 ± 0.07 0.26 ± 0.07 0.46 ± 0.09 2.03 ± 0.06 1.92 ± 0.07
P. aeruginosa 3C 2.15 ± 0.14 0.36 ± 0.08 * 0.45 ± 0.07 2.14 ± 0.12 2.43 ± 0.15
P. aeruginosa 3D 2.85 ± 0.13 0.22 ± 0.04 * 0.98 ± 0.07 2.73 ± 0.01 2.84 ± 0.76
P. aeruginosa 3E 2.86 ± 0.10 0.56 ± 0.10 0.35 ± 0.08 * 2.71 ± 0.09 2.84 ± 0.08
P. aeruginosa 3F 2.59 ± 0.22 0.55 ± 0.10 0.26 ± 0.08 * 2.71 ± 0.09 2.85 ± 0.08
P. aeruginosa 3M 2.18 ± 0.42 0.50 ± 0.06 0.25 ± 0.07 * 2.44 ± 0.07 1.86 ± 0.09
P. aeruginosa 3P 1.85 ± 0.81 0.54 ± 0.08 0.28 ± 0.04 * 2.45 ± 0.08 1.74 ± 0.04
P. aeruginosa ATCC 27858 2.28 ± 0.09 0.55 ± 0.06 0.26 ± 0.06 * 0.67 ± 0.10 0.75 ± 0.04
The 24 strains used in this part of the investigation were randomly selected as follows: 8 ESBL-
producing E. coli; 2 ESBL-producing and 6 carbapenamase (KPC)-producing K. pneumoniae; and 8
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carbapenamase- producing (MBL) P. aeruginosa. E. coli ATCC 25922, K. pneumoniae ATCC 700603, and P.
aeruginosa ATCC 27853 were used as susceptible strains. As shown in Table 1, a significant decrease in
biofilm production was observed for E. coli 7B, 7C, and ATCC 25922 treated with M. alternifolia EO and
for 5A, 5M, 6I, 7D, 7E strains treated with T. vulgaris EO (*P < 0.05). A significant decrease in biofilm
production was also observed (Table 2) for K. pneumoniae 1C–1G treated with M. alternifolia and for 1H,
1V, and ATCC 700603 strains treated with T. vulgaris EO, compared to positive control (*P < 0.05, **P <
0.01). Lastly, a significant decrease in biofilm production was observed (Table 3) for P. aeruginosa 3C
and 3D treated with M. alternifolia and for strains 3E and ATCC 27858 strains treated with T. vulgaris,
with respect to positive control (*P < 0.05).
3. Discussion
Both the difficulties in the treatment of chronic infections and the increase of antibiotic resistant strains
justify the increasing studies on new antibacterial compounds [25–28]. Interest is focused on naturally
active compounds, capable of contrasting the MDR strains and reducing the adhesion and formation of
their biofilms [29]. EOs’ inhibition of bacterial planktonic growth, including MDR strains, could be due
to their ability to degrade membrane proteins and cell permeability [30]. Regarding biofilm formation,
EOs are able to inhibit adhesion of bacterial cells at the first stage of biofilm formation, and some EOs also
have the capability to inhibit the activity of quorum sensing inhibitors (QSI) [31], a bacterial intracellular
communication system able to control the pathogenesis of many bacteria, including antibiotic resistance,
expression of virulence factors, and biofilm formation.
The aim of this research was to establish the antimicrobial activity of M. alternifolia, E. globulus,
M. piperita, and T. vulgaris EOs against resistant bacteria and their biofilms. M. alternifolia and T. vulgaris
EOs showed the best antibacterial activity against all strains tested, and a significant anti-biofilm
capability also emerged for the two most active EOs used in the test, as reported by other authors [32–35].
Several essential oils have been studied to date for their antimicrobial properties, and the choice of the
natural compounds is often based on what the environmental context can provide. In fact, within the
same compound, there may be many variables that can influence its antimicrobial activity, for example,
the soil where plants are grown and the extraction method. All information contributes to general and
global knowledge, but study results have a more direct impact at the country level. There are many
combinations of essential oils and of EOs and antibiotics to be investigated to find the best synergism
to fight microorganisms responsible for infections (in particular when protected by biofilm) through
the modulation of antibiotic resistance in the most problematic strains. More information will help to
reduce the gap between the lack of new synthetic molecules and the problem of antibiotic resistance,
which has considerable clinical and economic impact. Many researchers are trying to acquire and share
their results on this vast and important topic, as recently highlighted in a WHO document (2019) that
lists antibiotic resistance among the ten biggest plagues worldwide.
M. piperita EO displayed an antibacterial activity similar to that of T. vulgaris for the inhibition in the
bacterial growth zone (agar well diffusion assay), but lower MIC values. E. globulus EO presented a very
low antibacterial activity, so that EO and the M. piperita EO were not considered for further evaluations.
The data of MIC values confirmed the good activity of M. alternifolia and T. vulgaris EOs against
all resistant strains with respect to antibiotics, and the MICs of the two EOs were lower than those of
the antibiotics. The anti-mature biofilm evaluation also showed the capability of M. alternifolia and
T. vulgaris EOs to counteract MDR strains in sessile forms. The antibacterial activity of M. alternifolia EO
is attributed mainly to terpinen-4-ol, which is the major component of the oil and exhibits a favorable
hydrophobic/hydrophilic profile [33]. T. vulgaris EO is characterized by phenolic compounds, such as
thymol and carvacrol, and hydrocarbons, such as p-cymene and γ-terpinene [14–16]. In particular,
phenolic compounds are well-known for their strong antibacterial activity, since they are capable of
disintegrating bacterial outer membranes.
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The major antibacterial mechanism of M. alternifolia and T. vulgaris EOs is the morphological
alterations of permeability and the integrity of bacterial cell walls and membranes that lead to leakage
of intracellular materials, such as electrolytes, ATP, proteins, and DNA materials [36].
Interestingly, EOs have also been used as cleaning liquid for disinfecting medical equipment and
surfaces and are effective in controlling nosocomial infections [37]. In addition, they are used as aerosols
in operating blocks and waiting rooms for air cleaning to limit contamination [38]. Their pleasant
smell provides a pleasant feeling of psychic comfort for patients [39]. In a study from Benameur et al.,
the susceptibility of blaESBL-producing Enterobacteriaceae to Slovakian T. vulgaris EOs with or without
the antibiotic cefotaxime was assessed [40]. The authors reported the synergistic interaction of the
EOs in combination with the antibiotic against blaSHV-12-producing MDR E. coli and an additive effect
against ESBL-producing MDR Enterobacter cloacae.
4. Materials and Methods
4.1. Bacterial Strains and Phenotypic Identification
A total of 60 strains of K. pneumoniae, P. aeruginosa, and E. coli were obtained from the bacterial glycerol
stocks of Microbiology Laboratory of Hesperia Hospital, Modena, Italy. Sites of isolation included
urine, rectal swabs, and respiratory tracts. The microorganisms included 25 E. coli, 5 ESBL-producing
K. pneumoniae, 13 KPC-producing K. pneumoniae, and 20 MBL-producing P. aeruginosa. All strains from
the stock were subcultured, and the identification of species and antimicrobial susceptibility testing was
reconfirmed using the Vitek 2 system and AST-GN041 card (bioMerieux, Florence, Italy). The ESBL-
producing isolates were further reconfirmed by the phenotypic double-disc synergy test (DDST),
using both cefotaxime and ceftazidime alone and in combination with clavulanic, according to the Clinical
and Laboratory Standards Institute [41]. We applied the NG-Test CARBA 5 immunochromatographic
assay (NG Biotech, Guipry, France) for detecting the KPC, OXA-48-like, VIM, IMP, and NDM isolates.
4.2. Polymerase Chain Reaction and Sequencing of ESBL and Carbapenemase Genes
Bacterial isolates confirmed for their capacity to produce ESBLs were further analyzed by PCR.
DNA was extracted using a standard heat lysis protocol [42]. An overnight culture broth (1.5 mL) was
centrifuged at 14,000 rpm for 5 min, and we re-suspended the bacterial pellet in 500 mL of distilled
water. The cells were lysed by boiling them for 10 min at 95 ◦C, centrifuged at 14,000 rpm for 10 min,
and finally 2 µL of the supernatant were used as a template for PCR. ESBL genes (blaTEM, blaSHV, and
blaCTX-M) and carbapenamase genes (blaKPC; blaIMP, blaVIM, blaOXA-48-like, and blaNDM) were detected,
as previously reported [43,44]. PCR-positive amplicons were purified with the PCR Purification Kit
according to the manufacturer’s instructions (Qiagen, Milan, Italy) and directly sequenced using
amplification primers on the 3130 Genetic Analyzer (Applied Biosystem, Milan, Italy). Purification
and sequencing were carried out by Genex s.r.o. (CZ, Czech Republic). Sequence alignment and
analysis were performed online using the BLAST program of the National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov).
4.3. Antibacterial Activity Evaluation of the Essential Oils
4.3.1. Agar Disk Diffusion Assay
Essential oils (EOs) of M. alternifolia, E. globulus, M. piperita, and T. vulgaris were purchased from
Merck Life Science SRL, Milan, Italy. These oils were selected based on a literature survey and their use
in traditional medicine. Quality of the oils was ascertained to be more than 98% pure. The preliminary
determination of the antibacterial activity of the four EOs against all isolated bacteria was carried out by
using the agar disk diffusion assay, according to the standard procedure of the Clinical and Laboratory
Standards Institute [41]. Plates containing Muller Hinton Agar (MHE, bioMérieux, Florence, Italy) were
uniformly inoculated with 100 µL of 106 CFU/mL of each strain suspension. Then, sterile disks of 6 mm
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in diameter, containing 10 µL of each EO, were placed on the agar surfaces. After incubation at 37 ◦C
for 24 h, a clear zone of inhibition of the bacterial growth, expressed in millimeters (mm), was measured
to quantify the EOs antibacterial activity [45]. Cefotaxime (5 µg) and meropenem (10 µg) discs were
used as the positive control for E. coli, K. pneumoniae, and P. aeruginosa. A sterilized physiological saline
solution (5 µL) was used as negative control. The classified Gram-negative bacteria (ATCC-American
Type Culture Collection) E. coli ATCC 25922, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853
were used as positive control.
4.3.2. Minimum Inhibitory Concentration (MIC) Determination
The MIC evaluation was determined against all the microbial strains following the guidelines
of the Clinical and Laboratory Standards Institute [41], with slight modifications. The assay was
performed in sterile 96-well microplates by dispensing into each well 95 µL of tryptic soy broth, (TSB,
bioMerieux, Florence, Italy) and 5 µL of bacterial suspensions, to final inoculums concentrations of
106 CFU/mL. Each EO was diluted in TSB containing 0.5% Tween 80 (v/v) and 100 µL was added to wells
to give final EO concentrations ranging from 0.25 to 512 µL/mL [46]. The last well, containing 195 µL
of nutrient broth and 5 µL of bacterial strain without EO was used as negative control. The antibiotics
cefotaxime and meropenem diluted in nutrient broth with strains added were used as positive control.
The plates were incubated at 37 ◦C for 24 h. The MIC was defined as the lowest concentration of the
EO that inhibited visible growth of the tested microorganisms after optical density (OD) measured at
570 nm, using a microtiter plate reader. The MIC values were expressed as µg/mL, by considering the
density value for each EO. All the experiments were performed in triplicate.
4.4. Essential Oils’ Activity on Biofilm
The antibiofilm activity of two EOs, M. alternifolia, and T. vulgaris, chosen on the basis of
the best antibacterial activity seen in the previous assays, was tested on 2-day-old pre-formed
biofilms of 24 strains, randomly selected as follows: 8 ESBL-producing E. coli; 2 ESBL-producing and
6 carbapenamase (KPC)-producing K. pneumoniae; and 8 carbapenamase-producing (MBL) P. aeruginosa.
As susceptible strains, E. coli ATCC 25922, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853
were used. The mature biofilm was obtained by growing the strains on 96-well polystyrene microtiter
plates inoculated with 200 µL of 18-h-old bacterial culture containing a cell count of approximately
106 CFU/mL. The TSB medium was refreshed every 24 h, and after biofilm formation, the medium was
gently aspirated, and plates were washed three times with a sterile phosphate-buffered saline solution
(PBS, pH 7.2) to remove planktonic bacteria. The two EOs and the two antibiotics cefotaxime and
meropenem, used as positive control, were added at the respective MIC concentration and incubated
for 24 h at 37 ◦C. The residual biofilm was determined by the crystal violet staining method [47].
For fixation of the biofilms, 150 µL of methanol for 15 min was added, and the supernatant was
removed again. Then, 150 µL of crystal violet (CV) solution at 0.1% was added to each well and, 15 min
later, the excess dye was removed by washing the plates three times with sterile PBS. The bound crystal
violet was released by adding 200 µL of 33% acetic acid followed by incubation for 10 min at room
temperature. The optical density (OD) was measured at 570 nm using a microplate reader (Sunrise
Tecan, Grödig, Austria). TSB with bacterial culture added was used as the positive control and all
determinations were performed in triplicate.
4.5. Statistical Analysis
All the experiments were carried out in triplicate, and the bacterial count was performed on
three plates. All data are presented as the means ± SD. A Kruskal–Wallis test with Dunn’s multiple
comparisons test was used to analyze differences among positive results obtained using M. alternifolia
and T. vulgaris EOs, meropenem, and cefotaxime treatment for each strain of each species. All statistical
analyses were performed with GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA). *P <
0.05 was considered significant.
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5. Conclusions
In conclusion, the results that emerged from the present investigation and other existing data on
essential oils show the wide range of antimicrobial activity against MDR bacteria. These results may
be considered as a potential starting-point for additional studies on the activity for application of these
natural compounds in drugs, food, and cosmetics, in combination with nanomaterials and antibiotics,
as newer and more efficient antimicrobials able to closely interact with microorganisms.
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